A major NHS trial of the Galleri blood test has not met its main objective, according to its developer, Grail. The test, which is being evaluated in around 142,000 patients, aims to detect up to 50 types of cancer through a simple blood sample — often before symptoms appear.
The trial was designed to determine whether the test could reduce diagnoses of late-stage cancers, particularly stages three and four, when the disease is harder to treat. While the study did not achieve its primary goal of significantly lowering the combined rate of these advanced cancers, the results were not without promise.
A secondary analysis indicated that stage four cancer diagnoses alone fell by roughly 20% among those offered the test. This suggests that some of the most aggressive cancers may have been detected earlier, potentially improving treatment options and outcomes. Although researchers stress that any survival benefit remains unproven, the findings point to meaningful progress in early detection efforts.
When the programme launched, NHS England described it as the beginning of a potential revolution in cancer screening. While further evidence is needed before widespread adoption, the trial provides valuable insights and reinforces the growing potential of blood-based genomic testing to transform how cancer is diagnosed and managed.
